ORIGINAL PAPER
Free Access
First‐trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell‐free DNA testing
ABSTRACT
Objective
To define risk cut‐offs with corresponding detection rates (DR) and false‐positive rates (FPR) in screening for trisomy 21 using maternal age and combinations of first‐trimester biomarkers in order to determine which women should undergo contingent maternal blood cell‐free (cf) DNA testing.
Methods
From singleton pregnancies undergoing screening for aneuploidies at three UK hospitals between March 2006 and May 2012, we analyzed prospectively collected data on the following biomarkers: fetal nuchal translucency thickness (NT) and ductus venosus pulsatility index for veins (DV‐PIV) at 11 + 0 to 13 + 6 weeks' gestation and serum free β‐human chorionic gonadotropin (β‐hCG), pregnancy‐associated plasma protein‐A (PAPP‐A), placental growth factor (PlGF) and alpha‐fetoprotein (AFP) at 8 + 0 to 13 + 6 weeks. Estimates of risk cut‐offs, DRs and FPRs were derived for combinations of biomarkers and these were used to define the best strategy for contingent cfDNA testing.
Results
In contingent screening, detection of 98% of fetuses with trisomy 21 at an overall invasive testing rate < 0.5% can be potentially achieved by offering cfDNA testing to about 36%, 21% and 11% of cases identified by first‐line screening using the combined test alone, using the combined test with the addition of serum PlGF and AFP and using the combined test with the addition of PlGF, AFP and DV‐PIV, respectively.
Conclusions
Effective first‐trimester screening for trisomy 21, with DR of 98% and invasive testing rate < 0.5%, can be potentially achieved by contingent screening incorporating biomarkers and cfDNA testing. Copyright © 2013 ISUOG. Published by John Wiley & Sons Ltd.
Citing Literature
Number of times cited: 60
- K. O. Kagan, F. Sroka, J. Sonek, H. Abele, K. Lüthgens, M. Schmid, P. Wagner, S. Brucker, D. Wallwiener and M. Hoopmann, First‐trimester risk assessment based on ultrasound and cell‐free DNA vs combined screening: a randomized controlled trial, Ultrasound in Obstetrics & Gynecology, 51, 4, (437-444), (2018).
- Valentina Vinante, Bettina Keller, Evelyn A. Huhn, Dorothy Huang, Olav Lapaire and Gwendolin Manegold‐Brauer, Impact of nationwide health insurance coverage for non‐invasive prenatal testing, International Journal of Gynecology & Obstetrics, 141, 2, (189-193), (2018).
- Tianhua Huang, Wendy S. Meschino, Shamim Rashid, Alan Dennis, Ellen Mak-Tam and Howard Cuckle, Enhanced First Trimester Aneuploidy Screening with Placental Growth Factor and Alpha Feto-Protein: Detection of Trisomies 18 and 13, Journal of Obstetrics and Gynaecology Canada, 10.1016/j.jogc.2018.01.007, (2018).
- Jonathan B. Carmichael, Hsiao‐Pin Liu, David Janik, Terrence W. Hallahan, Kypros H. Nicolaides and David A. Krantz, Expanded conventional first trimester screening, Prenatal Diagnosis, 37, 8, (802-807), (2017).
- M. M. Gil, V. Accurti, B. Santacruz, M. N. Plana and K. H. Nicolaides, Analysis of cell‐free DNA in maternal blood in screening for aneuploidies: updated meta‐analysis, Ultrasound in Obstetrics & Gynecology, 50, 3, (302-314), (2017).
- Philipp Wagner, Markus Hoopmann and Karl Oliver Kagan, Moderne Konzepte des Ersttrimester-Screenings, gynäkologie + geburtshilfe, 10.1007/s15013-017-1139-6, 22, 2, (14-23), (2017).
- Tianhua Huang, Wendy S. Meschino, Mari Teitelbaum, Shelley Dougan and Nan Okun, Enhanced First Trimester Screening for Trisomy 21 with Contingent Cell-Free Fetal DNA: A Comparative Performance and Cost Analysis, Journal of Obstetrics and Gynaecology Canada, 39, 9, (742), (2017).
- Karl Oliver Kagan, Jiri Sonek, Philipp Wagner and Markus Hoopmann, Principles of first trimester screening in the age of non-invasive prenatal diagnosis: screening for chromosomal abnormalities, Archives of Gynecology and Obstetrics, 10.1007/s00404-017-4459-9, 296, 4, (645-651), (2017).
- Zeynep Güldem Ökem, Gökçen Örgül, Berna Tari Kasnakoglu, Mehmet Çakar and M.Sinan Beksaç, Economic analysis of prenatal screening strategies for Down syndrome in singleton pregnancies in Turkey, European Journal of Obstetrics & Gynecology and Reproductive Biology, 219, (40), (2017).
- Marcin Wiechec, Anna Knafel, Agnieszka Nocun, Ewa Wiercinska, Artur Ludwin and Inga Ludwin, What are the most common first-trimester ultrasound findings in cases of Turner syndrome?, The Journal of Maternal-Fetal & Neonatal Medicine, 30, 13, (1632), (2017).
- Susannah Maxwell, Peter O'Leary, Jan E. Dickinson and Graeme K. Suthers, Diagnostic performance and costs of contingent screening models for trisomy 21 incorporating non‐invasive prenatal testing, Australian and New Zealand Journal of Obstetrics and Gynaecology, 57, 4, (432-439), (2017).
- R. Douglas Wilson, Liona C. Poon and Alessandro Ghidini, Current controversies in prenatal diagnosis 3: is there still a value in a nuchal translucency screening ultrasound in conjunction with maternal plasma non‐invasive cell‐free DNA testing?, Prenatal Diagnosis, 36, 1, (20-24), (2015).
- D. Oepkes, J. L. Bartha, M. Schmid and Y. Yaron, Benefits of contingent screening vs primary screening by cell‐free DNA testing: think again, Ultrasound in Obstetrics & Gynecology, 47, 5, (542-545), (2016).
- M. M. Gil, R. Revello, L. C. Poon, R. Akolekar and K. H. Nicolaides, Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell‐free DNA test contingent on results from first‐trimester combined test, Ultrasound in Obstetrics & Gynecology, 47, 1, (45-52), (2015).
- F. E. Bredaki, M. Mataliotakis, A. Wright, D. Wright and K. H. Nicolaides, Maternal serum alpha‐fetoprotein at 12, 22 and 32 weeks' gestation in screening for pre‐eclampsia, Ultrasound in Obstetrics & Gynecology, 47, 4, (466-471), (2016).
- A. Perales‐Marín, J. Morales‐Roselló and R. Quiroga, Re: Clinical implementation of routine screening for fetal trisomies in the UK NHS: cell‐free DNA test contingent on results from first‐trimester combined test, Ultrasound in Obstetrics & Gynecology, 47, 6, (788-789), (2016).
- M. M. Gil, R. Revello, L. C. Poon, R. Akolekar and K. H. Nicolaides, Reply, Ultrasound in Obstetrics & Gynecology, 47, 6, (789-789), (2016).
- Semir Kose, Dilek Cımrın, Nuri Yıldırım, Ozge Aksel, Pembe Keskinoglu, Elcin Bora, Tufan Cankaya and Sabahattin Altunyurt, Analysis of first‐trimester combined test results in preparation for a cell‐free fetal DNA era, International Journal of Gynecology & Obstetrics, 135, 2, (187-191), (2016).
- U. Friebe-Hoffmann and K. Lato, Fetale DNA-Analyse aus mütterlichem Blut, Der Gynäkologe, 49, 11, (879), (2016).
- Lucia Rosignoli and Gabriele Tonni, Should cell‐free fetal DNA be included in first trimester screening (FTS) for common trisomy? A possible scenario on 6697 women screened over 10 years, Journal of Evaluation in Clinical Practice, 22, 6, (903-910), (2016).
- Emily Suskin, Laura Hercher, Kathleen Erskine Aaron and Komal Bajaj, The Integration of Noninvasive Prenatal Screening into the Existing Prenatal Paradigm: a Survey of Current Genetic Counseling Practice, Journal of Genetic Counseling, 25, 5, (1032), (2016).
- Niels Tørring, First trimester combined screening – focus on early biochemistry, Scandinavian Journal of Clinical and Laboratory Investigation, 10.1080/00365513.2016.1200131, 76, 6, (435-447), (2016).
- Pe’er Dar, Hagit Shani and Mark I. Evans, Cell-free DNA, Clinics in Laboratory Medicine, 36, 2, (199), (2016).
- Susannah Maxwell, Ian James, Jan E. Dickinson and Peter O'Leary, First trimester screening cut‐offs for noninvasive prenatal testing as a contingent screen: Balancing detection and screen‐positive rates for trisomy 21, Australian and New Zealand Journal of Obstetrics and Gynaecology, 56, 1, (29-35), (2016).
- Jennifer Alphonse, Jenny Cox, Jillian L. Clarke, Philip J. Schluter and Andrew McLennan, Retrospective 2D frontomaxillary facial angle measurements in trisomy 21 fetuses during routine first‐trimester screening, Sonography, 2, 1, (8-13), (2015).
- A. Alberti, L. J. Salomon, M. Le Lorc'h, A. Couloux, L. Bussières, S. Goupil, V. Malan, E. Pelletier, C. Hyon, F. Vialard, P. Rozenberg, P. Bouhanna, J. F. Oury, T. Schmitz, S. Romana, J. Weissenbach, M. Vekemans and Y. Ville, Non‐invasive prenatal testing for trisomy 21 based on analysis of cell‐free fetal DNA circulating in the maternal plasma, Prenatal Diagnosis, 35, 5, (471-476), (2015).
- Jonathan Carmichael, David Krantz, Hsiao‐Pin Liu, David Janik and Terrence Hallahan, Incorporation of dried blood alpha fetoprotein into traditional first trimester Down syndrome screening service, Prenatal Diagnosis, 35, 7, (703-708), (2015).
- Glenn E. Palomaki, Elizabeth E. Eklund, Louis M. Neveux and Geralyn M. Lambert Messerlian, Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures, Prenatal Diagnosis, 35, 8, (789-796), (2015).
- Tianhua Huang, Alan Dennis, Wendy S. Meschino, Shamim Rashid, Ellen Mak‐Tam and Howard Cuckle, First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy‐associated plasma protein A, free‐β human chorionic gonadotrophin, placental growth factor, and α‐fetoprotein, Prenatal Diagnosis, 35, 7, (709-716), (2015).
- Jan M. M. Van Lith, Brigitte H. W. Faas and Diana W. Bianchi, Current controversies in prenatal diagnosis 1: NIPT for chromosome abnormalities should be offered to women with low a priori risk, Prenatal Diagnosis, 35, 1, (8-14), (2015).
- Wilfried Gyselaers, Frank Hulstaert and Mattias Neyt, Contingent non‐invasive prenatal testing: an opportunity to improve non‐genetic aspects of fetal aneuploidy screening, Prenatal Diagnosis, 35, 13, (1347-1352), (2015).
- M. M. Gil, G. Giunta, E. A. Macalli, L. C. Poon and K. H. Nicolaides, UK NHS pilot study on cell‐free DNA testing in screening for fetal trisomies: factors affecting uptake, Ultrasound in Obstetrics & Gynecology, 45, 1, (67-73), (2014).
- K. O. Kagan, D. Wright and K. H. Nicolaides, First‐trimester contingent screening for trisomies 21, 18 and 13 by fetal nuchal translucency and ductus venosus flow and maternal blood cell‐free DNA testing, Ultrasound in Obstetrics & Gynecology, 45, 1, (42-47), (2014).
- M. I. Evans, J. D. Sonek, T. W. Hallahan and D. A. Krantz, Cell‐free fetal DNA screening in the USA: a cost analysis of screening strategies, Ultrasound in Obstetrics & Gynecology, 45, 1, (74-83), (2014).
- F. E. Bredaki, C. Sciorio, A. Wright, D. Wright and K. H. Nicolaides, Serum alpha‐fetoprotein in the three trimesters of pregnancy: effects of maternal characteristics and medical history, Ultrasound in Obstetrics & Gynecology, 46, 1, (34-41), (2015).
- Howard Cuckle1, Eugene Pergament and Peter Benn, Maternal Serum Screening for Chromosomal Abnormalities and Neural Tube Defects, Genetic Disorders and the Fetus, (483-540), (2015).
- XIAOLI LOU, YANQIANG HOU, DONGYU LIANG, LIANG PENG, HONGWEI CHEN, SHANYUAN MA and LURONG ZHANG, A novel Alu-based real-time PCR method for the quantitative detection of plasma circulating cell-free DNA: Sensitivity and specificity for the diagnosis of myocardial infarction, International Journal of Molecular Medicine, 35, 1, (72), (2015).
- Wybo Dondorp, Guido de Wert, Yvonne Bombard, Diana W Bianchi, Carsten Bergmann, Pascal Borry, Lyn S Chitty, Florence Fellmann, Francesca Forzano, Alison Hall, Lidewij Henneman, Heidi C Howard, Anneke Lucassen, Kelly Ormond, Borut Peterlin, Dragica Radojkovic, Wolf Rogowski, Maria Soller, Aad Tibben, Lisbeth Tranebjærg, Carla G van El and Martina C Cornel, Non-invasive prenatal testing for aneuploidy and beyond: challenges of responsible innovation in prenatal screening, European Journal of Human Genetics, 23, 11, (1438), (2015).
- Howard Cuckle, Peter Benn and Eugene Pergament, Cell-free DNA screening for fetal aneuploidy as a clinical service, Clinical Biochemistry, 48, 15, (932), (2015).
- Nicholas J Wald and Jonathan P Bestwick, Performance of antenatal reflex DNA screening for Down’s syndrome, Journal of Medical Screening, 22, 4, (168), (2015).
- Gwendolin Manegold-Brauer, C. Berg, A. Flöck, A. Rüland, U. Gembruch and A. Geipel, Uptake of non-invasive prenatal testing (NIPT) and impact on invasive procedures in a tertiary referral center, Archives of Gynecology and Obstetrics, 292, 3, (543), (2015).
- M. M. Gil, M. S. Quezada, R. Revello, R. Akolekar and K. H. Nicolaides, Analysis of cell‐free DNA in maternal blood in screening for fetal aneuploidies: updated meta‐analysis, Ultrasound in Obstetrics & Gynecology, 45, 3, (249-266), (2015).
- N. Okun, M. Teitelbaum, T. Huang, C. S. Dewa and J. S. Hoch, The price of performance: a cost and performance analysis of the implementation of cell‐free fetal DNA testing for Down syndrome in Ontario, Canada, Prenatal Diagnosis, 34, 4, (350-356), (2014).
- Carla Davis, Howard Cuckle and Yuval Yaron, Screening for Down syndrome – incidental diagnosis of other aneuploidies, Prenatal Diagnosis, 34, 11, (1044-1048), (2014).
- Diana W. Bianchi, Dick Oepkes and Alessandro Ghidini, Current controversies in prenatal diagnosis 1: should noninvasive DNA testing be the standard screening test for Down syndrome in all pregnant women?, Prenatal Diagnosis, 34, 1, (6-11), (2013).
- M. Grande, R. Solernou, L. Ferrer, V. Borobio, J. M. Jimenez, M. Bennasar, A. Soler and A. Borrell, Is nuchal translucency a useful aneuploidy marker in fetuses with crown–rump length of 28–44 mm?, Ultrasound in Obstetrics & Gynecology, 43, 5, (520-524), (2014).
- Basky Thilaganathan, Editor's Note, Ultrasound in Obstetrics & Gynecology, 43, 1, (1-2), (2014).
- F. D'Antonio, A. Khalil, G. Pagani, A. T. Papageorghiou, A. Bhide and B. Thilaganathan, Crown–rump length discordance and adverse perinatal outcome in twin pregnancies: systematic review and meta‐analysis, Ultrasound in Obstetrics & Gynecology, 44, 2, (138-146), (2014).
- J. D. Sonek and H. S. Cuckle, What will be the role of first‐trimester ultrasound if cell‐free DNA screening for aneuploidy becomes routine?, Ultrasound in Obstetrics & Gynecology, 44, 6, (621-630), (2014).
- K E Pettit, A D Hull, L Korty, M C Jones and D H Pretorius, The utilization of circulating cell-free fetal DNA testing and decrease in invasive diagnostic procedures: an institutional experience, Journal of Perinatology, 10.1038/jp.2014.102, 34, 10, (750-753), (2014).
- Diana W. Bianchi, R. Lamar Parker, Jeffrey Wentworth, Rajeevi Madankumar, Craig Saffer, Anita F. Das, Joseph A. Craig, Darya I. Chudova, Patricia L. Devers, Keith W. Jones, Kelly Oliver, Richard P. Rava and Amy J. Sehnert, DNA Sequencing versus Standard Prenatal Aneuploidy Screening, New England Journal of Medicine, 370, 9, (799), (2014).
- Peter Benn, Non-Invasive Prenatal Testing Using Cell Free DNA in Maternal Plasma: Recent Developments and Future Prospects, Journal of Clinical Medicine, 3, 4, (537), (2014).
- Jean-Pierre Bernard, L.J. Salomon, Y. Ville, H.S. Cuckle, M. Bernard and C. Brochet, Reply, American Journal of Obstetrics and Gynecology, 210, 2, (172), (2014).
- Howard Cuckle, Steering the Course Between Optimal Policies and Practical Restraints, Journal of Fetal Medicine, 1, 1, (3), (2014).
- Matthew S. Payne and Sara Bayatibojakhi, Exploring Preterm Birth as a Polymicrobial Disease: An Overview of the Uterine Microbiome, Frontiers in Immunology, 5, (2014).
- Meredith Vanstone, Carol King, Barbra de Vrijer and Jeff Nisker, Non-Invasive Prenatal Testing: Ethics and Policy Considerations, Journal of Obstetrics and Gynaecology Canada, 36, 6, (515), (2014).
- Cinzia Rapino, Natalia Battista, Monica Bari and Mauro Maccarrone, Endocannabinoids as biomarkers of human reproduction, Human Reproduction Update, 10.1093/humupd/dmu004, 20, 4, (501-516), (2014).
- Kjell Åsmund Salvesen, Fosterdiagnostikk med blodprøver, Tidsskrift for Den norske legeforening, 134, 4, (388), (2014).
- Gwendolin Manegold-Brauer, Sinuhe Hahn and Olav Lapaire, What does next-generation sequencing mean for prenatal diagnosis?, Biomarkers in Medicine, 8, 4, (499), (2014).
- P. Benn, H. Cuckle and E. Pergament, Non‐invasive prenatal testing for aneuploidy: current status and future prospects, Ultrasound in Obstetrics & Gynecology, 42, 1, (15-33), (2013).
